ALPS Post-Market Study

Alkmaar, Leipzig, Paris, Singapore

Slider

Patient Demographics

32 Patients
Average age: 67 ± 14 years

Post-market Study - Demographics | amCharts

ALPS Post-Market Study - US

SVS WIfI High Risk

Measure of wound/ischemia/foot infection severity

Post-Market Study - WIfI Classification | amCharts

ALPS Post-Market Study - US
Less Severe
More Severe
Rutherford Class 5
Rutherford Class 6
No-Option CLTI

24-Month Outcomes1

Amputation-Free Survival (AFS), Survival, Freedom from Amputation (FFA)

(n=31)

Post-market Study - Survival, Freedom from Amputation Step | amCharts

6 Months

AFS = 84%
Survival = 94%
FFA = 87%

12 Months

AFS = 71%
Survival = 84%
FFA = 80%

24 Months

AFS = 67%
Survival = 80%
FFA = 80%

Complete Wound Healing
Procedural Success
Months Median Time to Wound Healing
1. Schmidt, A, Schreve, MA, Huizing, E, Del Giudice, C, Branzan, D, Ünlü, Ç & Kum, S. Midterm outcomes of percutaneous deep venous arterialization with a dedicated system for patients with no-option chronic limb-threatening ischemia: the ALPS multicenter study. Journal of Endovascular Therapy, 2020;1526602820922179.

LimFlow, Inc.
2934 Scott Boulevard
Santa Clara, CA 95054 USA

info@limflow.com
+1 (888) 478-7705
+1 (408) 898-1459

CAUTION: Investigational device. Limited by Federal law to investigational use.
©2020 LimFlow SA | Site designed by The Deciding Factor, Inc.